Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

DOI Web Site Web Site Web Site Web Site 2 Citations
  • Krista L. Lanctôt
    Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology University of Toronto Toronto Canada
  • Joan Amatniek
    Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton NJ USA
  • Sonia Ancoli‐Israel
    Department of Psychiatry University of California San Diego CA USA
  • Steven E. Arnold
    Interdisciplinary Brain Center, Massachusetts General Hospital and Harvard Medical School Charlestown MA USA
  • Clive Ballard
    Institute of Psychiatry, Psychology and Neuroscience, King's College London London UK
  • Jiska Cohen‐Mansfield
    Department of Health Promotion School of Public Health, Sackler Faculty of Medicine and Minerva Center for the Interdisciplinary Study of End of Life, Tel Aviv University Tel Aviv Israel
  • Zahinoor Ismail
    Department of Psychiatry Hotchkiss Brain Institute, University of Calgary Calgary Alberta Canada
  • Constantine Lyketsos
    Department of Psychiatry and Behavioral Sciences Johns Hopkins Medicine Institutes Baltimore MD USA
  • David S. Miller
    Bracket Global Wayne PA USA
  • Erik Musiek
    Department of Neurology Hope Center for Neurological Disorders, and Knight Alzheimer Disease Research Center, Washington University School of Medicine St. Louis MO USA
  • Ricardo S. Osorio
    Center for Brain Health, NYU Langone Medical Center New York NY USA
  • Paul B. Rosenberg
    Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore MD USA
  • Andrew Satlin
    Eisai, Inc. Woodcliff Lake NJ USA
  • David Steffens
    Department of Psychiatry University of Connecticut School of Medicine Farmington CT USA
  • Pierre Tariot
    Banner Alzheimer's Institute Phoenix AZ USA
  • Lisa J. Bain
    Elverson PA USA
  • Maria C. Carrillo
    Alzheimer's Association Chicago IL USA
  • James A. Hendrix
    Alzheimer's Association Chicago IL USA
  • Heidi Jurgens
    Alzheimer's Association Chicago IL USA
  • Brendon Boot
    Department of Neurology Brigham and Women's Hospital, Harvard University School of Medicine Boston MA USA

Description

<jats:title>Abstract</jats:title><jats:p>Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under‐recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.</jats:p>

Journal

Citations (2)*help

See more

Report a problem

Back to top